Department of Pharmacy, The Third Hospital of Jilin University, Jilin University, Changchun, 130033, Jilin, China.
Department of Pharmacy, The Third Hospital of Jilin University, Jilin University, Changchun, 130033, Jilin, China.
Res Social Adm Pharm. 2021 Jan;17(1):1978-1983. doi: 10.1016/j.sapharm.2020.04.001. Epub 2020 Apr 6.
The coronavirus disease-19 (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus that was first detected at the end of December 2019. The epidemic has affected various regions of China in different degrees. As the situations evolve, the COVID-19 had been confirmed in many countries, and made a assessment that it can be characterized as a pandemic by the World Health Organization on March 11, 2020. Drugs are the main treatment of COVID-19 patients. Pharmaceutical service offers drug safety ensurance for COVID-19 patients. According to COVID-19 prevention and control policy and requirements, combined with series of diagnosis and treatment plans, pharmacists in the first provincial-level COVID-19 diagnosis and treatment unit in Jilin Province in Northeast China have established the management practices of drug supply and pharmaceutical care from four aspects: personnel, drugs supply management, off-label drug use management and pharmaceutical care. During the outbreak, the pharmaceutical department of THJU completed its assigned workload to ensure drug supply. So far, no nosocomial infections and medication errors have occurred, which has stabilized the mood of the staff and boosted the pharmacists' confidence in fighting the epidemic. For the treatment of COVID-19, pharmacists conducted adverse reaction monitoring and participated in the multidisciplinary consultation of COVID-19. Up to now, the COVID-19 patients admitted to THJU have not shown any new serious adverse reactions and been cured finally. The hospital pharmacy department timely adjusted the work mode, and the formed management practices is a powerful guarantee for the prevention and control of the COVID-19 epidemic. This paper summarized the details and practices of drug supply and pharmaceutical services management to provide experience for the people who involving in COVID-19 prevention and contain in other abroad epidemic areas.
新型冠状病毒肺炎（COVID-19）是由新型严重急性呼吸系统综合征冠状病毒引起的，该病毒于 2019 年 12 月底首次被发现。该疫情已在中国各地区造成不同程度的影响。随着形势的发展，COVID-19 已在许多国家得到确认，并于 2020 年 3 月 11 日被世界卫生组织评估为大流行。药物是 COVID-19 患者的主要治疗方法。药学服务为 COVID-19 患者提供药物安全保障。根据 COVID-19 防控政策和要求，结合一系列诊断和治疗方案，中国东北地区吉林省首家省级 COVID-19 诊断和治疗单位的药师从人员、药品供应管理、超说明书用药管理和药学服务四个方面建立了药品供应和药学服务管理的实践。在疫情期间，THJU 的药剂科完成了其指定的工作量，以确保药品供应。到目前为止，未发生医院感染和用药错误，稳定了员工情绪，增强了药师抗击疫情的信心。在 COVID-19 的治疗中，药师进行了不良反应监测，并参与了 COVID-19 的多学科咨询。截至目前，收治于 THJU 的 COVID-19 患者未出现新的严重不良反应并最终治愈。医院药房部门及时调整了工作模式，形成的管理实践是 COVID-19 疫情防控的有力保障。本文总结了药品供应和药学服务管理的细节和实践，为参与 COVID-19 防控和其他国外疫区防控的人员提供经验。
